REFERENCES
1. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740-56.
2. Rubinstein MM, Brown KA, Iyengar NM. Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer 2021;125:495-509.
3. Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial. Diabetes Care 2018;41:1663-71.
4. Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes 2014;63:3891-905.
5. Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. How far beyond diabetes can the benefits of glucagon-like peptide-1 receptor agonists go? Cancers 2022;14:4651.
6. Kosowska A, Gallego-Colon E, Garczorz W, et al. Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells. Endocr Connect 2017;6:856-65.
7. Madsen MSA, Holm JB, Pallejà A, et al. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep 2019;9:15582.
8. Dizman N, Meza L, Bergerot P, et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 2022;28:704-12.
9. Trakoonsenathong R, Kunprom W, Aphivatanasiri C, et al. Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo. Sci Rep 2024;14:13726.
10. Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity. JAMA Oncol 2024;10:256-8.
11. Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open 2024;7:e2421305.
12. Zhao HJ, Jiang X, Hu LJ, et al. Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells. J Mol Endocrinol 2020;64:103-13.
13. Nørgaard CH, Friedrich S, Hansen CT, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement 2022;8:e12268.
14. Benjamin DJ, Haslam A, Prasad V. Cardiovascular/anti-inflammatory drugs repurposed for treating or preventing cancer: a systematic review and meta-analysis of randomized trials. Cancer Med 2024;13:e7049.
